Patents by Inventor Arnold Heynen

Arnold Heynen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10596176
    Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 24, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Mark Firman Bear, Kevin R. Duffy, Donald E. Mitchell, Ming-Fai Fong, Arnold Heynen, Jeffrey P. Gavornik
  • Publication number: 20170065598
    Abstract: Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.
    Type: Application
    Filed: August 9, 2016
    Publication date: March 9, 2017
    Applicants: Massachusetts Institute of Technology, Dalhousie University
    Inventors: Mark Firman Bear, Kevin R. Duffy, Donald E. Mitchell, Ming-Fai Fong, Arnold Heynen, Jeffrey P. Gavornik
  • Publication number: 20160375006
    Abstract: The present disclosure provides methods of using GSK3?-selective inhibitors for treating Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder. The GSK3?-selective inhibitors include compounds of Formula I-A. The present disclosure also provides methods of using GSK3?-selective inhibitors for treating a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder. The GSK3?-selective inhibitors include compounds of Formula I-B.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Edward Scolnick, Jeffrey R. Cottrell, Florence Fevrier Wagner, Edward Holson, Michael C. Lewis, Mark Firman Bear, Laura Stoppel, Arnold Heynen
  • Publication number: 20120159656
    Abstract: The present invention provides, in some aspects, methods for identifying agents useful in treating disorders or conditions associated with cognitive deficits. In some aspects, the invention provides methods for detecting a cognitive deficit in a subject.
    Type: Application
    Filed: April 23, 2010
    Publication date: June 21, 2012
    Applicant: Galenea Corp.
    Inventors: David J. Gerber, Jonathan M. Levenson, Margaret E. Levin, Arnold Heynen